The historical rank and industry rank for Scholar Rock Holding's Net Cash per Share or its related term are showing as below:
SRRK'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.03 Med: 5.51 Max: 33.38
Current: 4.77
During the past 8 years, the highest Price-to-Net-Cash Ratio of Scholar Rock Holding was 33.38. The lowest was 1.03. And the median was 5.51.
SRRK's Price-to-Net-Cash is ranked worse than 56.66% of 863
companies
in the Biotechnology industry
Industry Median: 3.94
vs SRRK: 4.77
Scholar Rock Holding Net Cash per Share Historical Data
The historical data trend for Scholar Rock Holding's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scholar Rock Holding's Net Cash per Share
For the Biotechnology subindustry, Scholar Rock Holding's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding's Price-to-Net-Cash Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's Price-to-Net-Cash falls into.
Scholar Rock Holding Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Scholar Rock Holding's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (NAS:SRRK) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Scholar Rock Holding Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Scholar Rock Holding's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Scholar Rock Holding (Scholar Rock Holding) Business Description
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRK has been successfully added to your 